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Objective: The aim of this study was to clarify the role of pancreatic surgery
during the COVID-19 pandemic to optimize patients’ and clinicians’ safety
and safeguard health care capacity.
Summary Background Data: The COVID-19 pandemic heavily impacts
health care systems worldwide. Cancer patients appear to have an increased
risk for adverse events when infected by COVID-19, but the inability to
receive oncological care seems may be an even larger threat, particularly in
case of pancreatic cancer.
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Methods: An online survey was submitted to all members of seven international pancreatic associations and study groups, investigating the impact of
the COVID-19 pandemic on pancreatic surgery using 21 statements (April,
2020). Consensus was defined as >80% agreement among respondents and
moderate agreement as 60% to 80% agreement.
Results: A total of 337 respondents from 267 centers and 37 countries spanning
5 continents completed the survey. Most respondents were surgeons (n ¼ 302,
89.6%) and working in an academic center (n ¼ 286, 84.9%). The majority of
centers (n ¼ 166, 62.2%) performed less pancreatic surgery because of the
COVID-19 pandemic, reducing the weekly pancreatic resection rate from 3
[interquartile range (IQR) 2–5] to 1 (IQR 0–2) (P < 0.001). Most centers
screened for COVID-19 before pancreatic surgery (n ¼ 233, 87.3%). Consensus
was reached on 13 statements and 5 statements achieved moderate agreement.
Conclusions: This global survey elucidates the role of pancreatic surgery
during the COVID-19 pandemic, regarding patient selection for the surgical
and oncological treatment of pancreatic diseases to support clinical decisionmaking and creating a starting point for further discussion.
Keywords: ampullary adenocarcinoma, CA19-9, chronic pancreatitis,
COVID-19, distal bile duct cancer, duodenal adenocarcinoma, hospital
volume, intensive care unit, intraductal papillary mucinous neoplasms,
minimally invasive surgery, neoadjuvant treatment, pancreatic cancer,
pancreatic necrosis, pancreatic neuroendocrine tumor, pancreatic surgery,
pandemic, respectability, SARS-CoV-2

(Ann Surg 2020;272:e87–e93)

T

he World Health Organization (WHO) declared a pandemic of
coronavirus disease (COVID-19) (SARS-CoV-2) on March 11,
2020.1 The rapid spread of COVID-19 infections heavily impacts
health care systems worldwide, resulting in limitations in both
hospital and intensive care unit (ICU) capacity.2 As a result, this
pandemic not only affects COVID-19 patients, but strikes the entire
health care system including the care for patients with pancreatic
cancer and other pancreatic diseases.3
Recent large series suggest an increased risk for cancer patients to
develop severe complications when infected by COVID-19, including
those who were treated with surgery or chemotherapy in the last month.4
Pursuing oncological care exposes both health care professionals and
vulnerable patients to become infected by COVID-19. However, the
inability to receive medical and/or surgical care seems to be an equal
threat for cancer patients as well.5 The highly aggressive biology of
pancreatic cancer requires the continuation of oncological care during
the COVID-19 pandemic,6,7 but an unambiguous strategy is needed to
support health care professionals in clinical decision-making.
www.annalsofsurgery.com | e87
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Therefore, this international survey study aimed to clarify the
role of pancreatic surgery during the COVID-19 pandemic through
21 statements, aiming to optimize safety for patients and clinicians,
and safeguard health care.

METHODS

the number of responses per country. Most respondents were working
in an academic center (n ¼ 286, 84.9%) and the majority of
participants were surgeons (n ¼ 302, 89.6%). See Table 1 for the
characteristics of the respondents. The median annual hospital and
individual surgeon volume of pancreatic resections were 75 (IQR
46–140) and 35 (IQR 20–60), respectively.

Survey

Impact of COVID-19 Pandemic

An online survey was designed and submitted to all members
of 7 international pancreatic associations and study groups: the
Pancreas Club, European Pancreatic Club, Chinese Pancreatic Surgery Association, European Consortium on Minimally Invasive
Pancreatic Surgery, Study Group of Preoperative Therapy for Pancreatic Cancer, Study Group of Pancreatic Ductal Adenocarcinoma
with Peritoneal Metastasis, and International Study Group on Cystic
Tumors of the Pancreas using Google Forms (Google LLC, Menlo
Park CA). Both surgeons and nonsurgeons (eg, gastroenterologists
and medical oncologists) were asked to participate in this survey to
balance the discussion.
The survey consisted of 36 questions on baseline characteristics,
the local impact of the COVID-19 pandemic on pancreatic surgery (ie,
number of pancreatic resections, triage, and screening), and 21 statements about the role of pancreatic surgery in the current era of the
COVID-19 pandemic. Each statement had to be appraised using 3
options: agree, disagree, and uncertain. See Text – Supplemental
Digital Content 1, http://links.lww.com/SLA/C199 for the survey.
The survey was conducted in the first 2 weeks of April 2020.
Nonrespondents were reminded twice because of the rapid developments in the current COVID-19 crisis and need for novel policy
development a relatively short time window was used. Respondents
were asked to register their name and institution to prevent overlap of
members between the above-mentioned associations. The response
rate could not be calculated since associations submitted the survey
themselves. All study procedures were reviewed and approved by the
Colorado Multiple Institutional Review Board (COMIRB) (protocol
#20-0843) at the University of Colorado.

During the peak of the COVID-19 pandemic, 67.8% (n ¼ 181)
of centers prioritized between different types of pancreatic resections. Before pancreatic surgery, most centers screened patients for
COVID-19 (n ¼ 233, 87.3%), whereas some centers did not (n ¼ 31,
11.6%). See Table 2 for the preoperative COVID-19 screening
strategy. The majority of centers (n ¼ 166, 62.2%) performed less
pancreatic surgery as consequence of the COVID-19 pandemic.
From these centers, the weekly numbers of pancreatic resections
decreased from 3 (IQR 2–5) to 1 (IQR 0–2) (P < 0.001). In addition,
30.7% (n ¼ 51) of responding centers performed no pancreatic
surgery at all.

Definitions
Pancreatic ductal adenocarcinoma, bile duct cancer, duodenal
and ampullary adenocarcinomas, intraductal papillary mucinous
neoplasms (IPMNs), and pancreatic neuroendocrine tumors (pNETs)
were defined in accordance to the WHO definitions.8,9 A hospital
was defined as a high-volume pancreatic center when performing
20 pancreatoduodenectomies annually.10 Consensus was defined
as >80% agreement among respondents and moderate agreement
was defined as 60% to 80% agreement among them.

Statistical Analysis
Variables were processed and analyzed using IBM SPSS
Statistics for Microsoft Windows version 26 (IBM Corp., Orchard
Road Armonk, NY). Data were reported as number with percentage
or as median with interquartile range (IQR). The weekly volume of
pancreatic resections before and during the COVID-19 pandemic
was compared, using the Wilcoxon signed-rank test for nonnormally distributed variables. Sensitivity analyses were performed
to investigate the influence of specialty, the type of center, and
continent. Statistical significance was considered as 2-tailed P value
<0.050.

RESULTS
Participants
A total of 337 respondents from 267 centers and 37 countries
spanning 5 continents completed the online survey. See Figure 1 for
e88 | www.annalsofsurgery.com

Statements
Consensus was reached on 13 from the 21 statements (62%)
and moderate agreement was achieved on 5 statements (24%). The
remaining 3 statements had an agreement <60%. See Tables 3 to 5
for the statement outcomes.

Sensitivity Analyses
The statement outcomes barely changed after excluding the
nonacademic centers, without any shifts in the 3 categories of
agreement. Exclusion of nonsurgeons lead to the movement of
statement 5—regarding the prioritization of patients with limited/
without comorbidity for surgery to increase the ICU capacity—to the
lowest group of agreement (61.1%–59.9%).
Analyzing the outcomes of Europe (n ¼ 149, 44.2%), Asia (n ¼
115, 34.1%), and the Americas (ie, North and South America) (n ¼ 71,
21.1%) separately demonstrated some changes in agreement. The
European respondents did not reach consensus on statement 3
(76.5% agreement) regarding the prioritization of patients based on
objective prognostic factors and comorbidity. In contrast to the overall
outcomes, Asia achieved consensus on statement 4 (81.7% agreement)
to prioritize each patient for pancreatic surgery, based on prognostic
factors. Whereas Europe agreed on the importance of high-volume
centers to operate high-risk patients during the COVID-19 pandemic
(87.9% agreement), both Asia (75.7% agreement) and the Americas
(76.1% agreement) did not reach consensus on statement 16. The
recommendation for preoperative screening on COVID-19 (statement
19) reached solely consensus (84.5% agreement) in the Americas. See
Table—Supplemental Digital Content 2–4, http://links.lww.com/SLA/
C200, http://links.lww.com/SLA/C201, http://links.lww.com/SLA/
C202, for the statement outcomes of Europe, Asia, and the Americas
separately.

DISCUSSION
This global survey study aimed to clarify the role of pancreatic
surgery during the COVID-19 pandemic through 21 statements. The
statements regarding patient selection for the oncological and surgical treatment of pancreatic diseases could assist clinicians in their
clinical decision-making and create a starting point for further
discussion.
A literature review was performed (see Table—Supplemental Digital Content 5, http://links.lww.com/SLA/C203 for the
search strategy) to evaluate the current evidence about pancreatic
surgery during the COVID-19 pandemic. Kutikov et al6 concluded
ß
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FIGURE 1. Number of responses per country.

that (suspected) pancreatic cancer does not allow any treatment
delay and, therefore, requires immediate surgical treatment, but did
not address (neo)adjuvant therapy. Patients with both COVID-19
and cancer or treated with chemotherapy/surgery in the last months
seem to be at risk for severe events (ie, ICU admission requiring
invasive ventilation, or death) in comparison to COVID-19 patients
without cancer, according to a Chinese series.4 Therefore, Liang
et al4 advised to postpone adjuvant chemotherapy or elective
surgery for stable cancer in endemic areas. In contrast, Ueda
et al7 emphasized that adjuvant therapy with curative intent for
solid tumors should proceed, and surgery needs prioritization as
ß
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well. This latter statement is supported by the Society of Surgical
Oncology (SSO), stating that hepato-pancreato-biliary malignancies are typically aggressive and, therefore, should not be considered as ‘‘elective’’ care.11 In addition, the Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) and the European Association of Endoscopic Surgery recommended to postpone all elective surgery with exception of surgical care for life
threatening diseases such as progressive malignancies.12 Nevertheless, the limited evidence regarding the role of pancreatic
surgery in the era of the COVID-19 pandemic underlines the need
for an international survey with clear statements, aiming to guide
www.annalsofsurgery.com | e89
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TABLE 1. Characteristics of Respondents
Age, y
Profession, n (%)
Surgeon
Gastroenterologist
Oncologist
Surgical resident
Others
Type of center, n (%)
Academic center
Nonacademic center
Experience as attending specialist, y
Scope of current clinical practice, n (%)
Hepato-pancreato-biliary surgery
Pancreatic surgery
Surgical oncology
General surgery
Gastrointestinal surgery
Gastroenterology
Medical oncology
Others

TABLE 2. Preoperative Screening for COVID-19
49 (41–55)
302
20
4
5
6

(89.6)
(5.9)
(1.2)
(1.5)
(1.8)

286 (84.9)
51 (15.1)
18 (9–25)
177
62
32
23
14
17
5
7

(52.5)
(18.4)
(9.5)
(6.8)
(4.2)
(5.0)
(1.5)
(2.1)



Median (interquartile range); n, number of respondents.

clinicians in their clinical decision-making. The statement outcomes of the present international expert survey revealed several
consensus statements as well as statements that need further
discussion.

Screening, n (%)
Including symptoms
Including CT chest
Including PCR
Including symptoms þ CT chest þ PCR
No screening, n (%)
Missing data, n (%)

233
184
104
113
55
31
3

(87.3)
(68.9)
(39.0)
(42.3)
(20.6)
(11.6)
(1.1)

CT indicates computer tomography; n, number of centers; PCR, polymerase chain
reaction.

Triage
Patients with increased risk for postoperative respiratory
failure should not be prioritized for surgery in absence of full hospital
capacity, according to consensus statement 6. In contrast, only 61%
agreement was reached on statement 5 comprising the proposition
for surgery only for patients with limited/without comorbidity to
minimize the use of ICU capacity for COVID-19 patients. The
American College of Surgeons (ACS) underlined consensus statement 6, stating that ‘‘For elective cases with a high likelihood of
postoperative ICU or respirator utilization, it will be more imperative that the risk of delay to the individual patient is balanced against
the imminent availability of these resources for patients with COVID19.’’13 The aggressive biology of pancreatic cancer justifies elective

TABLE 3. Statement Outcomes—Consensus
1) Every patient with pancreatic cancer who has already received full NAT should undergo pancreatic surgery,
unless surgical facilities and venue in the hospital are emergently reserved for the treatment of COVID-19
patients (ie, OR is used as ICU, OR personnel is inserted for ICU care).
3) If available resources are limited, surgery should be prioritized to certain patients with pancreatic cancer, based
on objective prognostic factors and patients’ comorbidity.17 The rest of the patients could continue to receive
NAT.
6) In absence of full hospital capabilities for respiratory support, patients with increased risk for postoperative
respiratory failure should not be prioritized for surgery.
7) Prolongation of the NAT needs to be evaluated for patients with pancreatic cancer who refuse surgery or are not
be prioritized for surgery. Reevaluation of resectability needs to be accessed as soon as necessary resources for
surgery are available.
9) In case of reduced hospital capacity, patients affected by IPMNs should be considered for surgery only when
there is a strong suspicion for cancer. In absence of a strong suspicion for cancer, these patients should be
surveilled.
10) Chronic pancreatitis surgery should be postponed, unless the patient is experiencing life-threating complications.
11) Patients requiring treatment for infected pancreatic necrosis should be evaluated carefully by a multidisciplinary
team, considering the current and projected availability of local resources and the approach that will most
expediently evacuate infected necrosis. When intervention is necessary, minimally invasive procedures should
receive preference if possible.
12) In absence of suspicion for malignancy, surgery for pNETs should be delayed.
13) In case of suspected malignant pNETs, surgery is recommended for patients when no other effective treatment
can be proposed.
14) In case of symptomatic pNETs, surgery can be proposed, according with the local hospital capabilities, if no
other effective treatment can be proposed to manage the symptoms.
16) Outcome of pancreatic surgery is superior in high-volume centers. In the event of the COVID-19 pandemic,
pancreatic surgery in high-risk patients should not be done in low-volume centers and these patients should be
referred to high-volume centers (20 PD/year) to reduce the risk of long hospital stay and major complications
that can require ICU care.
17) Patients who undergo pancreatic surgery during COVID-19 pandemic should be informed about the following
additional risks: COVID-19 infection during hospitalization, possible nonoptimal postoperative management (ie,
shortage of ICU beds), increased risk of COVID-19 related mortality due to surgery or the cancer condition.
20) Several recent reports showed that there is an increased risk of COVID-19 infection for surgeons and staff
during surgical procedures. We, therefore, recommend OR personnel to wear adequate protective features
during surgery.

Agree

Disagree

Uncertain

83.4%

9.2%

7.4%

84.3%

6.5%

9.2%

84.0%

7.1%

8.9%

92.3%

1.5%

6.2%

95.3%

3.9%

0.9%

98.5%
94.4%

0.9%
1.5%

0.6%
4.2%

90.2%
81.6%

5.0%
9.8%

4.7%
8.6%

92.0%

3.0%

5.0%

81.3%

6.8%

11.9%

93.5%

1.5%

5.0%

91.7%

4.2%

4.2%

Consensus was defined as >80% agreement among respondents. NAT indicates neoadjuvant therapy; PD, pancreatoduodenectomy.

e90 | www.annalsofsurgery.com
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TABLE 4. Statement Outcomes—Moderate Agreement
4) Objective prognostic factors (eg, levels of CA19–9, reduction of levels of CA19–9 after NAT, treatment
in academic centers) should be used to predict the prognosis for every patient with pancreatic cancer so
that prioritization can be made.
5) To prevent ICU bed overload and maximize the availability of ICU bed for COVID-19 patients, surgery
should be proposed to patients with limited/without comorbidity.
8) The recommendation for patients with distal bile duct cancer that require PD can be equivalent to those
for pancreatic cancer.
19) COVID-19 preoperative testing/screening (eg, chest CT, PCR) is recommended, but not mandatory. The
tests will be done according to the policy of the hospital.
21) Minimally invasive techniques can be performed in accordance to the risk reducing procedural advice of
Zheng et al22 since the current evidence regarding the increased risk of COVID-19 spreading in the OR
by minimally invasive techniques is limited.12

Agree

Disagree

Uncertain

68.8%

16.0%

15.1%

61.1%

24.9%

13.9%

70.6%

23.1%

6.2%

75.1%

19.0%

5.9%

64.1%

12.2%

23.7%

Moderate agreement was defined as 60% to 80% agreement among respondents. CA19–9 indicates cancer antigen 19–9; CT, computer tomography; NAT, neoadjuvant therapy;
PCR, polymerase chain reaction.

pancreatic surgery as indispensable care12 and, therefore, should not
be exclusively performed for very low risk patients as prevention to
overload hospital resources (see the section ‘‘Pancreatic cancer’’
below for further explanation and recommendations). This could be
the rationale for a low agreement on statement 5. The ACS emphasized that continuation of ‘‘elective’’ surgical care has to be frequently evaluated and adapted if needed, based on the impact of the
COVID-19 pandemic on local resources.13 A reliable and objective
model is needed to stratify patients and guide prioritization in
accordance to hospital capabilities, such as the recently developed
respiratory failure risk score for elective abdominal and vascular
surgery, that identified pancreatic surgery among others as an
independent risk factor for postoperative respiratory failure.14

Screening and Protection for COVID-19
Before pancreatic surgery, most centers represented in this
survey screened their patients for symptoms of COVID-19. No
consensus was reached to recommend COVID-19 preoperative
testing/screening (statement 19). This seems a plea to obligate some
type of screening, but not necessarily with PCR and/or computed
tomography chest, particularly considering SAGES. SAGES underlines the recommendation of the Corona Virus Global Surgical
Collaborative to perform some type of screening test for all patients
(even if asymptomatic and without risk factors) who will undergo a
surgical or interventional endoscopic procedure in institutions seeing
high volumes of COVID-19 patients.12 In addition, ACS advised to
wait for the results of COVID-19 testing in patients who may be
infected.13
Based on consensus, patients who will undergo pancreatic
surgery should be informed about the following additional risks:
COVID-19 infection during hospitalization, possible nonoptimal

postoperative management (ie, shortage of ICU beds), increased
risk of COVID-19 related mortality due to surgery or the cancer
condition (statement 17). Furthermore, this survey convincingly
recommends that operating room (OR) personnel have to wear
adequate protective features during surgery, considering their
increased risk for COVID-19 infection during surgical procedures
(statement 20).15,16

Pancreatic Cancer
According to the consensus statements for patients with
pancreatic cancer, each patient should be operated after completing
neoadjuvant therapy (statement 1), as is also advised by the SSO.11
However, patients should be prioritized based on objective prognostic factors and comorbidities in case of limited resources. If surgery is
postponed, patients should continue with neoadjuvant therapy (statement 3), but neoadjuvant therapy should not be used to select each
patient with nonmetastatic pancreatic cancer for surgery (statement
2). Subsequently, patients with postponed surgery need to be evaluated as soon as possible for surgery when resources are available
again (statement 7). Oba et al17 recently described the value of a new
nomogram for pancreatic cancer, estimating patients’ predicted
survival based on preoperative factors and confirmed the prognostic
power of known predictive factors. These models could be used for
prioritization of surgery for pancreatic cancer in case of limited
resources. However, no consensus was reached on statement 4 and 5
to prioritize each pancreatic cancer patient on comorbidity and
objective pancreas cancer-related prognostic factors, considering
the life threatening nature of pancreatic cancer. Nevertheless, statement 18—prioritization of COVID-19 patients with a better prognosis over pancreatic cancer patients adhering to the process of triage
for hospital resources and ICU beds—did not reach 60% agreement.

TABLE 5. Statement Outcomes——Low Agreement
2) Every patient affected by nonmetastatic pancreatic cancer, independent of the stage of disease (primary
resectable, borderline resectable, locally advanced) should receive NAT before surgery, so that the best
candidates can be selected and for surgical resection and resources allocation can be rationalized.
15) In case of duodenal and ampullary cancers, surgery can be postponed or neoadjuvant chemotherapy
could be considered, unless patients have life threating risks (ie, bleeding, bowel obstruction).
18) Adhering to the process of triage, hospital resources and ICU beds should be prioritized for COVID-19
patients with better prognosis over patients who undergo surgery for pancreatic cancer.

Agree

Disagree

Uncertain

59.6%

26.4%

13.9%

47.2%

40.4%

12.5%

56.1%

22.6%

21.4%

Low agreement was defined as <60% agreement among respondents. NAT indicates neoadjuvant therapy.
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However, the difficulty to prioritize between patients with severe
COVID-19 or resectable pancreatic cancer is conceivable. See the
section ‘‘Triage’’ for further explanation and recommendations.
Italy has demonstrated the feasibility of continuing crucial
cancer care during the COVID-19 pandemic, among others by
appropriate resource allocation and separate health care pathways
between COVID-19 patients and noninfected cancer patients, structured by performance criteria (eg, hospital volume).3,18

Periampullary Malignancies (Without Pancreatic
Cancer)
Statement 8 proposed to manage distal bile duct cancer as
equivalent to pancreatic cancer. However, the lack of consensus
(71%) implies that surgery might have slightly less priority in
comparison to pancreatic cancer since 23% of respondents disagreed on the other hand. The SSO stated that extrahepatic bile
duct cancer and ampullary and duodenal adenocarcinomas should
be operated as soon as feasible, regardless of the presence of
symptoms.11 However, a high disagreement rate (40%) was
reached on statement 15 for postponing surgery or giving neoadjuvant chemotherapy for duodenal and ampullary cancers in
absence of life threatening risks (ie, bleeding, bowel obstruction).
Since evidence is limited about the efficacy of neoadjuvant chemotherapy for these cancers so far and could not be deemed to
stable diseases,11 many physicians might thought these should be
resected as indicated.

Benign or Premalignant Pancreatic Diseases
Consensus was reached to postpone surgery for benign and
premalignant pancreatic diseases, including IPMNs, pNETs, chronic
pancreatitis, and infected pancreatic necrosis. Exceptions comprise
life threatening complications of chronic pancreatitis or infected
pancreatic necrosis, symptomatic pNETs without effective alternative treatment options, or pNETs or IPMNs with suspicion for
malignancy (statements 9–14).

High-Volume Care
Volume–outcome relationships in pancreatic surgery are well
established with shorter hospital stay and lower mortality in highvolume centers.10,19,20 Pancreatic surgery in high-risk patients
should not be performed in low-volume centers during the
COVID-19 pandemic, aiming to reduce the risk of long hospital
stay and major complications requiring ICU care (statement 16).
Remarkably, the sensitivity analysis revealed that only Europe
reached consensus in contrast to Asia and the Americas.

Minimally Invasive Surgery
Statement 21 demonstrated the limited evidence regarding
the safety of minimally invasive surgery, illustrated by the substantial
percentage of respondents who agreed (65%) or were uncertain
(24%). Although previous research has shown that laparoscopy
can lead to aerosolization of blood borne viruses,21,16,15 SAGES
advised to continue to perform minimally invasive surgery in accordance to their risk reducing procedural advice. SAGES will monitor
emerging evidence considering the limited evidence about the relative risk of COVID-19 spreading in the OR by minimally invasive
surgery in comparison to conventional open surgery.12 The ACS
mentioned that aerosol-generating procedures increase the risk for
OR personnel and may not be avoidable, but confirmed the insufficiency of evidence to recommend or discommend minimally invasive
surgery.13 Meanwhile, SAGES underlined the proven benefits of
minimally invasive surgery to reduce postoperative morbidity and
hospital stay and, therefore, should be strongly considered in
these patients.
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Strengths and Limitations
The strength of this survey is the global range of respondents,
representing a wide range of countries and continents. However, the
results should be interpreted in light of some limitations. First, only
10.4% nonsurgeons (eg, medical oncologists and gastroenterologists)
participated in this survey, which could possibly outbalance the
discussion regarding the oncological treatment of pancreatic diseases. Second, a relatively small group of 8 countries was responsible
for the majority of survey participants (76.6%). Third, only a
minority of participants represented the nonacademic centers.

CONCLUSIONS
In summary, this survey reached consensus on the majority of
statements for the role of pancreatic surgery during the COVID-19
pandemic to optimize safety for patients and clinicians and safeguard
health care capacity by prioritizing only the most relevant care for
patients with non-COVID-19 pancreatic diseases.
The statements maybe be updated, based on more solid
evidence about the management of periampullary cancers (ie distal
bile duct cancer, and duodenal and ampullary adenocarcinomas),
preoperative screening modalities, and the safety of minimally
invasive surgery in relation to the COVID-19 pandemic.
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